A multifaceted risk factor:

Addressing obesity's impact across the disease spectrum

2.8 million people die every year as a result of obesity. At the same time, investment in research and development for obesity therapies is ushering in a new era of effective medications for this disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.

Read the whitepaper

ICON survey report:

Trends and challenges in obesity research and clinical trials

This survey investigates the opinions, experiences and predictions of a variety of individuals best positioned to provide an overview of current obesity drug and device development — and where it is likely to go in the future. 

Read the survey report

Obesity blogs and media contributions

Interdisciplinary expertise in obesity research services

ICON’s highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including obesity, diabetes, cardiometabolic disorders and hepatology including MASH.

Explore ICON's obesity clinical trial services